Mediolanum International Funds Ltd Boosts Stock Position in IQVIA Holdings Inc. $IQV

Mediolanum International Funds Ltd boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,950 shares of the medical research company’s stock after purchasing an additional 10,506 shares during the period. Mediolanum International Funds Ltd’s holdings in IQVIA were worth $12,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Verdence Capital Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $3,612,000. Patton Fund Management Inc. bought a new stake in IQVIA in the second quarter worth $231,000. Heritage Investors Management Corp grew its stake in shares of IQVIA by 10.5% in the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock worth $16,500,000 after acquiring an additional 9,909 shares during the last quarter. Shell Asset Management Co. increased its holdings in shares of IQVIA by 78.7% during the second quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock valued at $1,459,000 after acquiring an additional 4,077 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Citigroup lifted their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Barclays lifted their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Evercore ISI increased their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $240.61.

IQVIA Stock Performance

IQV opened at $225.09 on Friday. The company’s 50 day moving average is $205.80 and its 200 day moving average is $180.82. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a market cap of $38.33 billion, a price-to-earnings ratio of 30.88, a PEG ratio of 2.43 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $228.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.